Proof-Of-Concept Investigation With a Neurosteroid Analog (Ganaxolone) as a Smoking Cessation Candidate

Smoking Cessation Clinical Trial

— Ganaxolone  

Official title:

Proof-Of-Concept Investigation With a Neurosteroid Analog (Ganaxolone) as a Smoking Cessation Candidate

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01857531
• Other study ID #: Pro00041533
• Secondary ID: 1P50DA027840-01A
• Status: Completed
• Phase: Phase 2
• First received: May 16, 2013
• Last updated: September 5, 2014
• Start date: June 2013
• Est. completion date: February 2014

Study information

• Verified date: September 2014
• Source: Duke University
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug AdministrationUnited States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

The purpose of this research study is to evaluate whether the investigational drug ganaxolone can help smokers quit smoking. Ganaxolone is a drug that has been investigated (in other research studies) for the treatment of seizures and migraines. This drug is considered investigational in the US.

Description:

The purpose of this proof-of-concept study is to evaluate whether expired air carbon monoxide (CO) will be reduced and smoking cessation success rates enhanced for smokers who receive the neurosteroid analog ganaxolone. The trial will be seeking preliminary indications of efficacy and tolerability in the smoking population and allow us to estimate effect sizes for future controlled trials.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 36
• Est. completion date: February 2014
• Est. primary completion date: July 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Have no known serious medical conditions;

• Are 18-65 years old;

• Smoke an average of at least 10 cigarettes per day;

• Have smoked at least one cumulative year;

• Have an expired air CO reading of at least 10ppm;

• Able to read and understand English;

• Express a desire to quit smoking in the next thirty days.

Potential subjects must agree to use acceptable contraception during their participation in this study.

Potential subjects must agree to avoid the following during their participation in this study:

• participation in any other nicotine-related modification strategy outside of this protocol;

• use of tobacco products other than cigarettes, including pipe tobacco, cigars, e-cigarettes, snuff, and chewing tobacco;

• use of experimental (investigational) drugs or devices;

• use of illegal drugs;

• use of opiate medications;

• consumption of grapefruit or grapefruit juice for the first six weeks of study participation;

• use of melatonin;

• use of sedating antihistamines for the first six weeks of study participation;

• use of alcohol during the first six weeks of study participation.

• use of benzodiazepines

Exclusion Criteria:

• Inability to attend all required experimental sessions;

• Inability to take oral drugs or adhere to medication regimens;

• Hypertension (systolic >140 mm Hg, diastolic >90 mm Hg);

• Hypotension with symptoms (systolic <90 mm Hg, diastolic <60 mm Hg).

• Coronary heart disease;

• Lifetime history of heart attack;

• Clinically significant cardiac rhythm disorder (irregular heart rhythm);

• Chest pains;

• Cardiac (heart) disorder;

• Extensive active skin disorder;

• Liver or kidney disorder;

• Gastrointestinal disease other than gastroesophageal reflux or heartburn;

• Active ulcers in the past 30 days;

• Currently symptomatic lung disorder/disease;

• Brain abnormality;

• Migraine headaches that occur more frequently than once per week;

• History of seizures;

• Recent, unexplained fainting spells;

• Problems giving blood samples;

• Diabetes (unless treated with diet and exercise alone);

• Current cancer or treatment for cancer in the past six months (except basal or squamous cell skin cancer);

• Other major medical condition;

• Current symptomatic psychiatric disease;

• Current depression;

• Current suicidal ideation or history of suicide attempt (in the past 5 years);

• Pregnant or nursing mothers;

• Use (within the past 30 days) of:

• Illegal drugs (or if the urine drug screen is positive),

• Experimental (investigational) drugs;

• Psychiatric medications including antidepressants, antipsychotics or any other medications that are known to affect smoking cessation (e.g. clonidine);

• Corticosteroids;

• Cytochrome P450 341 (CYP3A4) inhibitors and inducers;

• Smokeless tobacco (chewing tobacco, snuff), pipes or e-cigarettes;

• Wellbutrin, bupropion, Zyban, Chantix, varenicline, nicotine replacement therapy or any other smoking cessation aid.

• Use (within the past 14 days) of:

• dehydroepiandrosterone (DHEA), Pregnenolone or ganaxolone;

• Opiate medications for pain or sleep;

• Benzodiazepines or other drugs with significant sedating or anticholinergic activity;

• Use of more than one cigar a month;

• Regular alcohol use;

• Significant adverse reaction to nicotine patches in the past.

• Significant past adverse reaction to ganaxolone in the past.

• Current participation or recent participation (in the past 30 days) in another smoking study at our center or another research facility.

• Current participation in another research study.

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Smoking Cessation

Intervention

Drug:
• Ganaxolone
Pre-Quit Period: Beginning at Session P1, subjects will receive ganaxolone at a dose of 400mg total daily (200mg bid) for the first three days, 800mg total daily (400mg bid) for the next three days and 1200mg total daily (600mg bid) for the remainder of the first four weeks. Post-Quit Period: Following the quit-day, subjects will receive ganaxolone at a dose of (1200mg total daily) for the next week. Down-titration of ganaxolone will begin at post-quit week two. Subjects will receive ganaxolone at a dose of 800mg total daily (400mg bid) to take for three days and 400mg total daily (200mg bid) to take for three.
• Nicotine Patch
Pre-Quit Period: Beginning at Session P2, subjects will receive active 21mg/24h nicotine patches to apply daily for the next two weeks. Post-Quit Period: Following the quit-day, subjects will continue to apply active nicotine patches daily for the remainder of the study (21mg/24h for four weeks, 14mg/24h for one week, and 7mg/24h for one week).

Locations

Country	Name	City	State
United States	Duke Center for Smoking Cessation	Charlotte	North Carolina
United States	Duke Center for Smoking Cessation	Durham	North Carolina
United States	Duke Center for Smoking Cessation	Raleigh	North Carolina
United States	Duke Center for Smoking Cessation	Winston-Salem	North Carolina

Sponsors (2)

Lead Sponsor	Collaborator
Jed E. Rose	National Institute on Drug Abuse (NIDA)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Number of Participants Completing Continuous 2-week Abstinence From Smoking	Continuous two week abstinence from smoking at the first post-quit visit (approximately 2 weeks post quit date), based on self-reported abstinence confirmed by expired air CO.	2 Weeks post quit	No
Other	Number of Participants Completing Point Abstinence From Smoking Two Weeks After Quitting	Point abstinence from smoking two weeks post quit, based on self-reported abstinence during last seven days confirmed by expired air CO at first post-quit visit.	7 day point abstinence from smoking at 2 weeks post quit	No
Other	Number of Participants Completing Continuous 6-week Abstinence From Smoking	Continuous six week abstinence from smoking at final study visit (approximately 6 weeks post quit date), based on self-reported abstinence confirmed by expired air CO	6 Weeks post quit	No
Other	Number of Participants Completing Abstinence From Smoking During the Last Four Weeks of Treatment	End of treatment abstinence from smoking during the last four weeks of treatment, based on self-reported abstinence during last four weeks confirmed by expired air CO	4 Week abstinence from smoking at 6 weeks post quit	No
Primary	Percentage of Change in Expired Air Carbon Monoxide (CO) at End of Week 2	To evaluate the effects of ganaxolone on ad lib smoking by looking at the percent change in expired air CO at the end of week two (relative to baseline).	Baseline and 2 Weeks	No
Secondary	Percentage of Change in Expired Air Carbon Monoxide (CO) at End of Week 4	To evaluate the effects of ganaxolone as an augmentation treatment in conjunction with nicotine patch by looking at the percent change in expired air CO at the end of week four (relative to baseline).	Baseline and 4 Weeks	No